Developing a new antifungal treatment for oral and skin yeast infections
Official title: Preclinical Development of Occidiofungin for Treatment of Oral and Dermal Candidiasis
Funded at Sano Chemicals, INC · NIH-10919356 · Data updated 2026-11-12
This study is looking at a new antifungal treatment called occidiofungin, which could help people with tough-to-treat Candida infections that don’t respond to current medications, and it aims to make this treatment safer and more effective for those who need it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sano Chemicals, INC NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 1R42AI184022-01 |
| Project ID | NIH-10919356 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing recurrent or drug-resistant oral and dermal candidiasis.
✕Less likely to help
Patients with non-fungal infections or those who do not have candidiasis may not benefit from this research.
What this research studies
This research focuses on occidiofungin, a novel antifungal peptide that shows strong effectiveness against drug-resistant Candida species, which cause oral and skin infections. The project involves optimizing the production of occidiofungin and conducting detailed studies on its structure, activity, and safety. By testing its efficacy in preclinical models, the research aims to establish occidiofungin as a viable treatment option for patients suffering from recurrent or resistant candidiasis. The findings could lead to new therapeutic options for those who have not responded to existing antifungal treatments.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment for patients suffering from difficult-to-treat oral and skin yeast infections.
How similar studies have gone: Other research has shown promise with similar antifungal approaches, indicating potential for success with occidiofungin.
Where this research is happening
-
Sano Chemicals, INC
College Station, United States Active
Researchers
- Principal investigator: Smith, James Leif — Sano Chemicals, INC
- Study coordinator: Smith, James Leif
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.